Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
作者： Lakisha Moore-Smith , Andres Forero-Torres , Erica Stringer-Reasor
DOI: 10.1016/J.SUC.2018.04.004
关键词: Breast cancer subtype 、 Triple-negative breast cancer 、 Triple Negative Breast Neoplasms 、 Targeted therapy 、 Internal medicine 、 Mastectomy 、 Treatment options 、 Oncology 、 Medicine 、 Neoadjuvant therapy 、 Breast cancer
摘要: Breast cancer is the 2nd leading cause of cancer-related death in women United States. In general, advances targeted treatment for breast have improved over last twenty years, except triple-negative (TNBC) subtype. TNBC an aggressive subtype with limited options as compared to hormone positive cancers. Recently, genomic profiling shows promise aiding clinicians develop personalized agents. Prioritizing novel molecular-based therapies neoadjuvant setting may help investigators understand mechanisms resistance and ultimately improve patient outcomes TNBC.
sci-hub.se 参考文章(49)
Denise A. Yardley, Dianna L. Shipley, Nancy W. Peacock, Mythili Shastry, Rajiv Midha, Victor M. Priego, John D. Hainsworth, Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Research and Treatment. ,vol. 152, pp. 557- 567 ,(2015) , 10.1007/S10549-015-3482-4
Shunchao Yan, Xin Jiao, Huawei Zou, Kai Li, Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases Diagnostic Pathology. ,vol. 10, pp. 62- 62 ,(2015) , 10.1186/S13000-015-0296-Y
V. Diéras, M. Campone, D.A. Yardley, G. Romieu, V. Valero, S.J. Isakoff, H. Koeppen, T.R. Wilson, Y. Xiao, D.S. Shames, S. Mocci, M. Chen, P. Schmid, Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer Annals of Oncology. ,vol. 26, pp. 1904- 1910 ,(2015) , 10.1093/ANNONC/MDV263
Carey K. Anders, Vandana Abramson, Tira Tan, Rebecca Dent, The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 35, pp. 34- 42 ,(2016) , 10.14694/EDBK_159135
Priyanka Sharma, Sara López-Tarruella, Jose Angel García-Saenz, Claire Ward, Carol S. Connor, Henry L. Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Augusti Barnadas, Antoni C. Picornell, Maria del Monte-Millán, Milagros Gonzalez-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González del Val, Javier Cortes, Hugo Fuentes Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M. Perou, Jamie L. Wagner, Joshua M.V. Mammen, Marilee K. McGinness, Jennifer R. Klemp, Amanda L. Amin, Carol J. Fabian, Jaimie Heldstab, Andrew K. Godwin, Roy A. Jensen, Bruce F. Kimler, Qamar J. Khan, Miguel Martin, Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research. ,vol. 23, pp. 649- 657 ,(2017) , 10.1158/1078-0432.CCR-16-0162
Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Stephen Y. Chui, Kathleen A. Kemmer, Anthony D. Elias, Kirsten K. Edmiston, David M. Euhus, Barbara B. Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl Ewing, Richard Schwab, Julia Lyandres, Sarah E. Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura J. van ’t Veer, Meredith B. Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer The New England Journal of Medicine. ,vol. 375, pp. 23- 34 ,(2016) , 10.1056/NEJMOA1513749
Xiaoxian Li, Ceyda Sonmez Wetherilt, Uma Krishnamurti, Jing Yang, Yamin Ma, Toncred M. Styblo, Jane L. Meisel, Limin Peng, Momin T. Siddiqui, Cynthia Cohen, Ritu Aneja, Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer American Journal of Clinical Pathology. ,vol. 146, pp. 496- 502 ,(2016) , 10.1093/AJCP/AQW134
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, None, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 375, pp. 1823- 1833 ,(2016) , 10.1056/NEJMOA1606774
Brett Fleisher, Charlotte Clarke, Sihem Ait-Oudhia, Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer: Targets and Therapy. ,vol. 8, pp. 183- 197 ,(2016) , 10.2147/BCTT.S114659
Sung Gwe Ahn, Seung Jun Kim, Cheungyeul Kim, Joon Jeong, Molecular Classification of Triple-Negative Breast Cancer Journal of Breast Cancer. ,vol. 19, pp. 223- 230 ,(2016) , 10.4048/JBC.2016.19.3.223